Want to see INMB full AI Analyst Report?
INMB Stock Chart & Stats
$1.62
$0.11(6.79%)
At close: 4:00 PM EDT
$1.62
$0.11(6.79%)
Day’s Range― - ―
52-Week Range$1.09 - $2.48
Previous Close$1.86
Volume180.53K
Average Volume (3M)1.13M
Market Cap
$64.39M
Enterprise Value$26.55
Total Cash (Recent Filing)$18.41M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 04, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding27,753,790
10 Day Avg. Volume632,372
30 Day Avg. Volume1,130,494
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside393.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway De-riskingFormal MHRA alignment and pediatric plan approval clarify the evidence and submission path for Ebstracel. This reduces regulatory uncertainty, supports a conditional UK filing and creates a foundation for planned European and U.S. submissions.
Manufacturing And Supply ReadinessProgress toward commercial manufacturing and secured cord-tissue access addresses critical execution risks for a cell therapy. The expanded supply arrangement can support regulatory filings and future production across the UK, EU and U.S.
Clinical Differentiation In XPro ProgramStatistically significant MRI evidence of myelin-related treatment effects, combined with FDA Fast Track status, strengthens XPro's clinical and regulatory positioning. Biomarker enrichment may also support a more targeted development strategy in Alzheimer's disease.
Bears Say
Pre-commercial Revenue ProfileThe absence of recurring product revenue means INMB cannot currently fund operations through customers. Substantial losses will likely persist while programs advance, leaving outcomes dependent on successful approvals, commercialization or partnerships.
Cash Burn And Financing DependencePersistent operating and free-cash-flow deficits require external capital to sustain development. With runway extending only into Q2 2027, additional financing may be needed before key milestones mature, creating dilution and execution risk.
Delayed Confirmatory EvidenceThe confirmatory study's approximately 18-month duration delays full evidence for safety and efficacy, leaving regulatory and commercial confidence dependent on interim development. Slow enrollment of about 1–2 patients weekly could extend that timeline.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.09 and its highest was $2.48 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $64.39M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Nov 04, 2026 which is in 71 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on Aug 06, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.207 by $0.157.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.15.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 27,753,790 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.207. Following the earnings report the stock price went up 9.162%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (393.83% Upside)
$8.00 (393.83% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.60%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
INMB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong program‑level de‑risking and tangible operational progress: formal MHRA alignment, pediatric plan approval, manufacturing readiness for Ebstracel, strengthened IP and SAB, and encouraging XPro Phase 2 imaging results with FDA Fast Track designation. Financially the quarter showed a large improvement in reported loss driven by nonrecurring items and R&D rebates, and management is controlling burn. Major near‑term milestones (UK MAA submission, EMA and US filings) are well defined. Principal concerns are a limited cash runway into Q2 2027, reliance on one‑time rebates, enrollment pace for the confirmatory trial, and financing/valuation uncertainty that could lead to dilution. On balance, the operational and clinical accomplishments outweigh the financial timing risks, but successful execution of filings and financing will be critical.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$8.00
▲(393.83% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
10.81% Insiders
4.70% Mutual Funds
1.02% Other Institutional Investors
80.70% Public Companies and
Individual Investors